Japanese Biotech Stock News

TSE:4204
TSE:4204Industrials

Is Sekisui Chemical’s Completed ¥26.4b Buyback Altering The Investment Case For Sekisui Chemical (TSE:4204)?

Sekisui Chemical has now completed its previously announced share repurchase plan, buying back 10,000,000 shares (2.43% of shares) for ¥26,420.48 million by February 9, 2026. This completed buyback reduces the share count and may enhance per-share metrics, underlining management’s willingness to return capital to investors. Next, we’ll examine how the completion of this sizeable buyback program may influence Sekisui Chemical’s existing investment narrative. We've uncovered the 14 dividend...
TSE:4502
TSE:4502Pharmaceuticals

Takeda Pharmaceutical’s Valuation After FDA Priority Review And New AI Drug Discovery Collaboration

Takeda Pharmaceutical (TSE:4502) just cleared two meaningful milestones, with the U.S. FDA granting Priority Review for its narcolepsy type 1 candidate oveporexton and a new AI-focused drug discovery collaboration with Iambic. See our latest analysis for Takeda Pharmaceutical. The recent regulatory progress for oveporexton and the AI drug discovery partnership with Iambic come as Takeda’s shares trade at ¥5,609, with a 30-day share price return of 11.73%, a 90-day share price return of...
TSE:8987
TSE:8987Office REITs

A Look At Japan Excellent (TSE:8987) Valuation After New ¥100,000 Million Bond Shelf Registration

Japan Excellent (TSE:8987) has filed a shelf registration for up to ¥100,000 million in investment corporation bonds, giving it a multi-year funding option for property acquisitions, upkeep, refinancing, and day-to-day operations. See our latest analysis for Japan Excellent. That funding option lands at a time when the share price is around ¥151,000, with a modest 90 day share price return of 1.68% and a much stronger 1 year total shareholder return of 27.43%. This points to momentum that has...
TSE:7180
TSE:7180Banks

Assessing Kyushu Financial Group (TSE:7180) Valuation After Strong Profit Growth, Dividend Increases And Ongoing Buybacks

Kyushu Financial Group (TSE:7180) has just paired double-digit income growth and roughly 48% profit growth with expanding assets and equity, while reaffirming its dividend policy, higher total dividends, and continued share buybacks. See our latest analysis for Kyushu Financial Group. Those results and the January buybacks have arrived alongside strong price momentum, with a 30 day share price return of 25.82% and a 90 day gain of 56.48%. The 1 year total shareholder return of 104.23% points...
TSE:9434
TSE:9434Wireless Telecom

SoftBank’s Earnings per Share Gains Might Change The Case For Investing In SoftBank (TSE:9434)

SoftBank Corp. has reported past earnings for the nine months ended December 31, 2025, with sales of ¥5.20 trillion and net income of ¥485.52 billion, both higher than the previous year. The improvement in basic and diluted earnings per share from continuing operations suggests greater profit generation per share, which may influence how investors assess SoftBank’s earnings power. We’ll now examine how this growth in sales and net income shapes SoftBank’s broader investment narrative and...
TSE:8473
TSE:8473Capital Markets

Assessing SBI Holdings (TSE:8473) Valuation After Strong Earnings And Strium Tokenized Securities Launch

Event-driven update on SBI Holdings SBI Holdings (TSE:8473) has just reported significantly higher sales and net income for the nine months to December 31, 2025, while also teaming up with Startale Group to launch the Strium tokenized securities blockchain platform in Asia. See our latest analysis for SBI Holdings. SBI Holdings’ recent nine month earnings update and the launch of the Strium tokenized securities platform come after a 4.05% year to date share price return and a very strong 1...